Hikma Pharmaceuticals Plc with ticker (LON:HIK) now has a potential upside of 22.2% according to RBC Capital Markets.
RBC Capital Markets set a target price of 2,150 GBX for the company, which when compared to the Hikma Pharmaceuticals Plc share price of 1,759 GBX at opening today (22/11/2023) indicates a potential upside of 22.2%. Trading has ranged between 1,418 (52 week low) and 2,222 (52 week high) with an average of 461,882 shares exchanging hands daily. The market capitalisation at the time of writing is £3,885,466,940.
Hikma Pharmaceuticals PLC is a pharmaceutical company. The Company’s principal activities are the development, manufacturing, marketing and selling of a range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates through three segments: Injectables, Generics and Branded. Injectables segment supply hospitals across its markets with generic injectables, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). Generics segment supply oral and other non-injectable generic and specialty branded products in the United States retail market. Branded segment supply branded generics and in-licensed patented products in MENA. It also markets its products in Canada and, which includes approximately 25 sterile injectable products, three in-licensed ophthalmic products and a pipeline of seven additional products.
Hikma Pharmaceuticals Plc 22.2% potential upside indicated by RBC Capital Markets
- Written by: Charlotte Edwards
Latest Company News
Hikma Pharmaceuticals posted a 6% rise in H1 2025 revenue to $1.66 billion, supported by strong Injectables and Branded sales. Core operating profit declined 7% due to product mix and prior-year comparators, but the company expects a stronger H2.
Hikma Pharmaceuticals has received a Fitch upgrade to 'BBB' for its long-term issuer default rating, highlighting its financial strength and strategic position.
Hikma Pharmaceuticals reports strong 2024 results, with double-digit revenue growth, increased profits, and strategic acquisitions fueling optimism for 2025.
Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities.
Hikma Pharmaceuticals PLC provides a trading update ahead of its Annual General Meeting. CEO Riad Mishlawi highlights strong growth and momentum across the Group in 2024.
